<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03601143</url>
  </required_header>
  <id_info>
    <org_study_id>HE 7386/1-1</org_study_id>
    <nct_id>NCT03601143</nct_id>
  </id_info>
  <brief_title>Liquid Biopsy-based Detection of Resistance to Targeted Therapy in Prostate Cancer Patients</brief_title>
  <acronym>PEARL</acronym>
  <official_title>Liquid Biopsy-based Detection of Resistance to Targeted Therapy in Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will prospectively compare liquid-biopsy based methods for prediction of&#xD;
      resistance under androgen-receptor signaling inhibitors. The main goal is to determine the&#xD;
      optimal method to determine androgen-receptor variant 7 (AR-V7) status. In addition, the&#xD;
      investigators will explore novel other, AR-V7 independent mechanisms of resistance and their&#xD;
      predictive value for proper treatment. These are based on further AR splice variants, and on&#xD;
      neuroendocrine differentiation of prostate cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Androgen receptor signaling inhibitors (ARSi) have become available in the past years for the&#xD;
      treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and have&#xD;
      significantly improved their survival. Despite this improvement, initial or emerging&#xD;
      resistance to ARSi poses a major challenge in the treatment of these patients. There is&#xD;
      therefore an urgent medical need for early detection of treatment resistance.&#xD;
&#xD;
      Liquid biopsies - blood samples containing circulating tumor cells (CTCs) and nucleic acids&#xD;
      from the tumor - can provide information about such resistance. The investigators of this&#xD;
      study and others have shown that liquid biopsies can be used to detect the messenger RNA&#xD;
      (mRNA) of AR-V7, a splice variant of the androgen receptor (AR) that is insensitive to ARSi,&#xD;
      in whole blood, and that high levels of AR-V7 mRNA in mCRPC patients are predictive to&#xD;
      non-response to ARSi. Several liquid biopsy approaches involving different blood compartments&#xD;
      such as CTCs, exosomes, and whole blood have been used so far to detect AR-V7. However, it is&#xD;
      unclear which liquid biopsy approach or which combination of approaches is best to predict&#xD;
      resistance under ARSi therapy in the clinical setting. In addition, current approaches&#xD;
      explain only about half of resistant cases, suggesting that there are important&#xD;
      non-AR-V7-mediated causes of resistance.&#xD;
&#xD;
      In this study, the investigators aim at determining the optimal liquid biopsy approach to&#xD;
      detect AR-V7 and exploring novel ones for best possible prediction of resistance to ARSi. To&#xD;
      this end, the investigators will systematically explore relevant blood compartments in a&#xD;
      prospective cohort of mCRPC patients, quantify AR-V7 mRNA levels in each compartment, and&#xD;
      determine the diagnostic value of compartment-specific AR-V7 mRNA levels for predicting&#xD;
      response to subsequent ARSi therapy. The investigators will further explore the clinical&#xD;
      relevance of AR-V7 protein subcellular localization in CTCs for prediction of ARSi&#xD;
      resistance. In addition, novel other, AR-V7 independent mechanisms of resistance and their&#xD;
      predictive value for proper treatment will be explored. These are based on further AR splice&#xD;
      variants, and on neuroendocrine differentiation of prostate cancer cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate-specific antigen (PSA) decline &gt;=50%</measure>
    <time_frame>24 months</time_frame>
    <description>The optimal liquid biopsy-based test method to predict PSA response under AR-targeted therapy will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical progression-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>The optimal liquid biopsy-based test method to predict clinical progression-free survival under AR-targeted therapy will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>The optimal liquid biopsy-based test method to predict overall survival under AR-targeted therapy will be determined.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Castration-resistant Prostate Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples prior to a new line of AR-targeted therapy</intervention_name>
    <description>Blood will be drawn at baseline prior to a new line of AR-targeted therapy.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        metastatic castration-resistant prostate cancer patients planned for a new line of therapy&#xD;
        with androgen-receptor signaling inhibitors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed prostate adenocarcinoma&#xD;
&#xD;
          -  Castrate serum testosterone &lt;50ng/ml or &lt;1.7nmol/l under continued&#xD;
             androgen-deprivation therapy or surgical castration&#xD;
&#xD;
          -  Progressive disease at study entry in accordance with Prostate Cancer Working Group 3&#xD;
             criteria (PCWG3):&#xD;
&#xD;
               -  Biochemical progression: Three consecutive rises in PSA at least one week apart&#xD;
                  resulting in two 50% increases over the nadir, and a PSA &gt;1.0 ng/ml as minimal&#xD;
                  starting value, or&#xD;
&#xD;
               -  Radiologic progression: either two or more new bone lesions on bone scan or a new&#xD;
                  soft tissue lesion using RECIST (Response evaluation criteria in solid tumors).&#xD;
&#xD;
          -  Metastatic disease confirmed on computed tomography (CT) or bone scan&#xD;
&#xD;
          -  Planned treatment with ARSi (androgen-receptor signaling receptors)&#xD;
&#xD;
          -  Written informed consent of the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons who are in a dependency or employment relationship with the investigator or&#xD;
             sponsor&#xD;
&#xD;
          -  Planned additional concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias M Heck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christof Winter, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias M Heck, MD</last_name>
    <phone>+49894140</phone>
    <phone_ext>2508</phone_ext>
    <email>matthias.heck@tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christof Winter, MD PhD</last_name>
    <phone>+49894140</phone>
    <phone_ext>4765</phone_ext>
    <email>christof.winter@tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Technical University of Munich, Klinikum rechts der Isar, Department of Urology and Institute of Clinical Chemistry</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias M Heck, MD</last_name>
      <phone>+49894140</phone>
      <phone_ext>2508</phone_ext>
      <email>matthias.heck@tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Christof Winter, MD PhD</last_name>
      <phone>+49894140</phone>
      <phone_ext>4765</phone_ext>
      <email>christof.winter@tum.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Seitz AK, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, Ruland J, Winter C, Heck MM. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. Eur Urol. 2017 Nov;72(5):828-834. doi: 10.1016/j.eururo.2017.07.024. Epub 2017 Aug 14.</citation>
    <PMID>28818355</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

